

Curriculum Vitae

Date Prepared: July 9, 2019
Name: Christopher S. Nabel
Office Address: 55 Fruit Street, Suite 10B
Boston, MA 02114
Work Phone:
Work Email: cnabel@partners.org
Work FAX:
Place of Birth: Boston, MA, USA

Education

2008	AB, cum laude	Biochemical Sciences	Harvard College
2013	PhD	Cell and Molecular Biology (Rahul Kohli)	University of Pennsylvania
2015	MD	Medicine	University of Pennsylvania

Postdoctoral Training

2015-2017	Internal Medicine Resident	Brigham and Women's Hospital; Boston, MA
2017-	Clinical Oncology Fellow	Mass. General Hospital Cancer Center/ Dana- Farber Cancer Institute/Partners CancerCare; Boston, MA
2018-	Chief Fellow, MGH Cancer Center	
2018-	Postdoctoral Affiliate	Mass. Institute for Technology, Koch Institute for Integrative Cancer Research; Cambridge, MA

Committee Service

Local

2012-2014	MSTP Steering Committee	University of Pennsylvania
2017-	Health Professions Advisory Committee	Leverett House, Harvard College

Professional Societies

- For each professional society of which you have been a member indicate the following:
2014-2015 American Society of Hematology Member

Report of Scholarship

Peer reviewed publications in print or other media

1. Hollenhorst MA, Braun DA, Burtner CR, Cajigas I, Cunningham-Bussel AC, Eser, PO, **Nabel CS**, Tsai FD, Weeks LD, Michel T, Yialamas MA. (2019). Bridging the Divide: Development of a Student Grand Rounds at the Interface of Basic Science and Clinical Medicine. Academic Medicine. Accepted.
2. Fajgenbaum DC, Shilling D, Partridge HL, Pierson SK, Singh A, Langan RA, Ruth JR, **Nabel CS**, Stone K, Chaturvedi V, Okumura M, Schwarzer A, Jose FF, Hamerschlak N, Wertheim G, Cohen AD, Krymskaya V, Rubenstein AH, Kambayashi T, Jordan M, van Rhee F, Uldrick TS. (2019). PI3K/AKT/mTOR is a Novel Therapeutic Target in IL-6-blockade Refractory iMCD. JCI. Accepted.
3. **Nabel CS**, Sameroff SC, Shilling D, Alapat D, Ruth JR, Kawano M, Sato Y, Stone K, Spetalen S, Valdevieso, Feldman M, Chadburn A, Fossa A, van Rhee F, Lipkin WI, Fajgenbaum DC. (2019). Virome capture sequencing does not identify active viral infection in Unicentric and idiopathic Multicentric Castleman Disease. PloS One. Accepted.
4. **Nabel CS**, Severgnini M, Hung YP, Cunningham-Bussel A, Gjini E, Kleinstein K, Seymour LJ, Holland MK, Cunningham R, Felt KD, Vivero M, Rodig SJ, Massarotti EM, Rahma OE, Harshman LC. (2019). Anti-PD-1 immunotherapy-induced flare of a known underlying relapsing vasculitis mimicking recurrent cancer. The Oncologist. In Press. doi: 10.1634/theoncologist.2018-0633.
5. Schutsky EK, DeNizio JE, Hu P, Liu MY, **Nabel CS**, Fabyanic EB, Hwang Y, Bushman FD, Wu H, Kohli RM. (2018). Nondestructive, base-resolution sequencing of 5-hydroxymethylcytosine using a DNA deaminase. Nature Biotechnology. In Press. doi: 10.1038/nbt.4204.
6. Pierson SK, Stonestrom AJ, Shilling D, Ruth J, **Nabel CS**, Singh A, Ren Y, Stone K, Li H, van Rhee F, Fajgenbaum DC. (2018). Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease. American Journal of Hematology, 93(7)902-912.
7. Schutsky EK, **Nabel CS**, Davis AKF, DeNizio JE, Kohli RM. (2017). APOBEC3A efficiently deaminates methylated, but not TET-oxidized, cytosine bases in DNA. Nucleic Acids Research, 45(13):7655-7665.
8. **Nabel CS**, DeNizio JE, Carroll M, Kohli RM. (2017). DNA Methyltransferases Demonstrate Reduced Activity Against Arabinocytosine: Implications for Epigenetic Instability in AML. Biochemistry, 56(16):2166-2169.
9. Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong RS, Pierson S, Paessler M, Rossi JF, Ide M, Ruth J, Croglia M, Suarez A, Krymskaya V, Chadburn A, Colleoni G, Nasta S, Jayanthan R, **Nabel CS**, Casper C, Dispenzieri A, Fosså A, Kelleher D, Kurzrock R, Voorhees P, Dogan A, Yoshizaki K, van Rhee F, Oksenhendler E, Jaffe ES, Elenitoba-Johnson KS, Lim MS. (2017). International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood, 129(12):1646-1657.
10. Liu AY, **Nabel CS**, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, Krymskaya VP, Kelleher D, Rubenstein AH, Fajgenbaum DC. (2016). Idiopathic Multicentric Castleman’s Disease: a systematic literature review. Lancet Haematology, 3(4):e163-175.

11. Iwaki N, Fajgenbaum DC, **Nabel CS**, Gion Y, Kondo E, Kawano M, Masunari T, Yoshida I, Moro H, Nikkuni K, Takai K, Matsue K, Kurosawa M, Hagihara M, Saito A, Okamoto M, Yokota K, Hiraiwa S, Nakamura N, Nakao S, Yoshino T, Sato Y. (2016). Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV8-negative multicentric Castleman Disease. *American Journal of Hematology*, 91(2):220-6.
12. Crawford DJ, Liu MY, **Nabel CS**, Cao XJ, Garcia BJ, Kohli RM. (2016). Tet2 catalyzes stepwise 5-methylcytosine oxidation by an iterative and de novo mechanism. *Journal of the American Chemical Society*, 138(3):730-3.
13. Fajgenbaum DF, van Rhee F, **Nabel CS**. (2014). HHV8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. *Blood*, 123(19):2924-33.
14. **Nabel CS**, Schutsky EK, Kohli RM. (2014). Molecular targeting of mutagenic AID and APOBEC deaminases. *Cell Cycle*, 13(2):171-2.
15. Sun Z, Feng D, Fang B, Mullican SE, You SH, Lim HW, Everett LJ, **Nabel CS**, Li Y, Selvakumaran V, Won KJ, Lazar MA. (2013). Deacetylase-independent function of HDAC3 in transcription and metabolism requires nuclear receptor corepressor. *Molecular Cell*, 52(6):769-82.
16. **Nabel CS**, Lee J, Wang LC, Kohli RM. (2013). Nucleic acid determinants for selective deamination of DNA over RNA by activation-induced deaminase. *Proceedings of the National Academy of Science*, 110(35):14225-30.
17. **Nabel CS**, Jia H, Ye Y, Shen L, Goldschmidt HL, Stivers JT, Zhang Y, Kohli RM. (2012). AID/APOBEC deaminases discriminate against modified cytosines implicated in DNA demethylation. *Nature Chemical Biology*, 8(9):751-8.
18. Dollive S, Peterfreund GL, Sherrill-Mix S, Bittinger K, Sinha R, Hoffmann C, **Nabel CS**, Hill DA, Artis D, Bachman MA, Custers-Allen R, Grunberg S, Wu GD, Lewis JD, Bushman FD. (2012). A toolkit for quantifying eukaryotic rRNA gene sequences from human microbiome samples. *Genome Biology*, 13(7):R60.
19. **Nabel CS**, Manning SA, Kohli RM. (2012). The curious chemical biology of cytosine: deamination, methylation, and oxidation as modulators of genomic potential. *ACS Chemical Biology*, 7(1):20-30.
20. **Nabel CS**, Kohli RM. (2011). Molecular biology. Demystifying DNA demethylation. *Science*, 333(6047):1229-30.
21. Fabozzi G*, **Nabel CS***, Dolan MA, Sullivan NJ. (2011). Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the RNA interference pathway. *Journal of Virology*, 85(6):2515-23.

* Indicates equal contribution

[Thesis](#)

Nabel C.S., "Nucleic acid determinants of cytosine deamination by AID/APOBEC enzymes in immunity and epigenetics" (January 1, 2013). Dissertations available from ProQuest. Paper AAI3609217.
<http://repository.upenn.edu/dissertations/AAI3609217>

[Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings](#)

Nabel CS, Vander Heiden MG. (2019). *Evaluation of Allopurinol Synergy with Cytarabine in Human Acute Myeloid Leukemia Cancer Cell Lines.* Keystone Symposium on Tumor Metabolism. Keystone, CO.

Nabel CS, Sameroff SC, Shilling D, Alapat D, Ruth JR, Kawano M, Sato Y, Stone K, Spetalen S, Valdevieso, Feldman M, Chadburn A, Fossa A, van Rhee F, Lipkin WI, Fajgenbaum DC. (2017). *Virome Capture Sequencing in Castleman Disease identifies associations with Herpesviridae family members but no novel viruses.* American Society of Hematology Annual Meeting. Atlanta, GA.

Nabel CS, Denizio JE, Carroll M, Kohli RM. (2016). *DNA methyltransferases demonstrate reduced activity against Arabinosylcytosine: Implications for epigenetic instability in AML.* American Association of Physicans/American Society of Clinical Investigation/American Physician Scientist Association. Chicago, IL.

Nabel CS, Jia H, Ye Y, Shen L, Goldschmidt HL, Stivers JT, Zhang Y, Kohli RM. (2012). *AID/APOBEC enzymes discriminate against bulky 5-substituted cytosines for deamination: Implications for DNA demethylation.* Keystone Symposium: Mutations, Malignancy and Memory; Boston, MA. NIAID Travel Scholarship.

Nabel CS, Wang LC, Kohli RM. (2012). *The molecular basis for selective deamination of DNA over RNA by AID/APOBEC enzymes is determined by nucleotide sugar pucker and flexibility.* Keystone Symposium: Mutations, Malignancy and Memory; Boston, MA. NIAID Travel Scholarship.